Daily home fortification with iron as ferrous fumarate versus NaFeEDTA: a randomised, placebo-controlled, non-inferiority trial in Kenyan children. by Teshome, Emily M et al.
Teshome, EM; Andang’o, PEA; Osoti, V; Terwel, SR; Otieno, W;
Demir, AY; Prentice, AM; Verhoef, H (2017) Daily home fortifica-
tion with iron as ferrous fumarate versus NaFeEDTA: a randomised,
placebo-controlled, non-inferiority trial in Kenyan children. BMC
Med, 15 (1). p. 89. ISSN 1741-7015 DOI: 10.1186/s12916-017-0839-z
Downloaded from: http://researchonline.lshtm.ac.uk/3851061/
DOI: 10.1186/s12916-017-0839-z
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE Open Access
Daily home fortification with iron as ferrous
fumarate versus NaFeEDTA: a randomised,
placebo-controlled, non-inferiority trial in
Kenyan children
Emily M. Teshome1,2*, Pauline E. A. Andang’o3, Victor Osoti4, Sofie R. Terwel5, Walter Otieno6, Ayşe Y. Demir7,
Andrew M. Prentice1,2 and Hans Verhoef1,2,5
Abstract
Background: We aimed to show the non-inferiority of home fortification with a daily dose of 3 mg iron in the
form of iron as ferric sodium ethylenediaminetetraacetate (NaFeEDTA) compared with 12.5 mg iron as encapsulated
ferrous fumarate in Kenyan children aged 12–36 months. In addition, we updated a recent meta-analysis to assess
the efficacy of home fortification with iron-containing powders, with a view to examining diversity in trial results.
Methods: We gave chemoprevention by dihydroartemisinin-piperaquine, albendazole and praziquantel to 338
afebrile children with haemoglobin concentration ≥70 g/L. We randomly allocated them to daily home fortification
for 30 days with either placebo, 3 mg iron as NaFeEDTA or 12.5 mg iron as encapsulated ferrous fumarate. We
assessed haemoglobin concentration (primary outcome), plasma iron markers, plasma inflammation markers and
Plasmodium infection in samples collected at baseline and after 30 days of intervention. We conducted a meta-analysis
of randomised controlled trials in pre-school children to assess the effect of home fortification with iron-containing
powders on anaemia and haemoglobin concentration at end of intervention.
Results: A total of 315 children completed the 30-day intervention period. At baseline, 66.9% of children had inflammation
(plasma C-reactive protein concentration >5 mg/L or plasma α1-acid glycoprotein concentration >1.0 g/L);
in those without inflammation, 42.5% were iron deficient. There was no evidence, either in per protocol analysis or
intention-to-treat analysis, that home fortification with either of the iron interventions improved haemoglobin
concentration, plasma ferritin concentration, plasma transferrin receptor concentration or erythrocyte zinc
protoporphyrin-haem ratio. We also found no evidence of effect modification by iron status, anaemia status and
inflammation status at baseline. In the meta-analysis, the effect on haemoglobin concentration was highly
heterogeneous between trials (I2: 84.1%; p value for test of heterogeneity: <0.0001).
Conclusions: In this population, home fortification with either 3 mg iron as NaFeEDTA or 12.5 mg iron as encapsulated
ferrous fumarate was insufficiently efficacious to assess non-inferiority of 3 mg iron as NaFeEDTA compared to 12.5 mg
iron as encapsulated ferrous fumarate. Our finding of heterogeneity between trial results should stimulate subgroup
analysis or meta-regression to identify population-specific factors that determine efficacy.
Trial Registration: The trial was registered with ClinicalTrials.gov (NCT02073149) on 25 February 2014.
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Background
In 2011, the World Health Organisation (WHO) recom-
mended daily home fortification with iron (12.5 mg as a
ferrous salt) in populations where the prevalence of
anaemia in children younger than 5 years of age is ≥20%
[1], which covers most developing countries [2]. This
recommendation was based on a meta-analysis of rando-
mised controlled trials showing moderate quality evi-
dence for an effect on anaemia and haemoglobin
concentration [3].
The WHO-recommended dose of 12.5 mg iron was
established to meet almost 90% of the estimated total
iron requirement of children aged 6–18 months [4].
Several trials have shown, however, that supplementation
or food fortification with iron at this dose can increase
rates of hospital admissions [5] as well as diarrheal and
respiratory diseases [6]. In addition, it can produce a
potentially more pathogenic gut microbiota profile that
is associated with gut inflammation [7, 8]. Ingestion of
ferrous salts also frequently causes mild gastrointestinal
adverse effects (e.g. constipation, nausea, vomiting and
epigastric discomfort) that may reduce adherence to
treatment [9]. The frequency and severity of such effects
depend on dose and dosage schedule [10, 11], may be
due to oxidative stress [12] and appear to be reduced
when iron is taken with food.
By comparison, ingestion of a low dose of highly bio-
available iron (3 mg iron as ferric sodium ethylenedi-
aminetetraacetate (NaFeEDTA)) may result in similar or
even higher quantities of absorbed iron [13] and may be
non-inferior in its effect on iron status. It may have the
advantage that reduced amounts of ingested iron may
reduce proliferation of pathogenic gut bacteria, produce
less oxidative stress and increase tolerability and adher-
ence [14]. In addition, iron as NaFeEDTA has been re-
ported to cause less oxidative stress than an equimolar
dose of iron as ferrous sulphate [15]. No study has so far
compared the efficacy of daily home iron fortification
with 12.5 mg iron as encapsulated ferrous fumarate
versus 3 mg iron as NaFeEDTA.
In malaria-endemic areas, WHO has recommended
that iron interventions should be implemented in con-
junction with measures to control malaria [1], because
there is substantial evidence that iron interventions can
increase malaria rates in young children [16].
We aimed to show non-inferiority of home fortification
with 3 mg iron as NaFeEDTA compared with 12.5 mg
iron as encapsulated ferrous fumarate in children aged
12–36 months under cover of chemoprevention against
malaria. We conducted a pre-specified analysis to explore
to what extent efficacy depended on baseline iron markers
(haemoglobin concentration, plasma concentrations of
ferritin and soluble transferrin receptor measured), be-
cause iron absorption is known to depend on iron status.
Lastly, we used results from our present study and
other recent reports to update the meta-analysis by
Salam et al. [5], with a view to examining diversity in
study results.
Methods
Details of study methods are described in the statistical
analysis plan (Additional file 1). During study implementa-
tion, there were no major amendments to the protocol.
Study setting and subjects
Fieldwork was conducted between January 2014 and
December 2014 in KisumuWest District, Kenya. Malaria
is highly endemic in the area [17, 18], with virtually all
infections due to Plasmodium falciparum. In children
aged 1–4 years, the prevalence of infections due to P.
falciparum has been reported to range between 39% and
63% [19]. Previous trials in the area have shown that
iron supplementation resulted in increased haemoglobin
concentrations among pre-school children, suggesting
that iron deficiency is common [20–22].
Study design
This was a randomised, double-blind, non-inferiority
trial with three arms: 3 mg iron as NaFeEDTA
(experimental treatment); 12.5 mg iron as encapsu-
lated ferrous fumarate (active control treatment); and
placebo. We included the placebo arm to demonstrate
superiority of the investigational drug over placebo
(proof of efficacy) [23]. The study was conceived as
an explanatory trial to evaluate efficacy with maximal
compliance.
Data collection timelines and field procedures
Community health workers invited parents of children
aged 12–36 months old for screening at the research
clinic. During screening, research assistants measured
height and length within 0.1 cm using wooden measur-
ing boards (UNICEF, Copenhagen, Denmark) and weight
to the nearest 100 g using a Salter scale (UNICEF,
Copenhagen, Denmark). They also administered a stan-
dardised form to collect vital data and household charac-
teristics data. Medical staff conducted a medical
examination and collected venous blood (4 mL) in tubes
containing Li-heparin for subsequent determination of
iron biomarkers and Plasmodium infection. Children
who attained the eligibility criteria were given pre-
medications 3 days before randomisation to treatment
allocation.
Pre-medications
Medical staff administered drugs to prevent malaria and
to control anaemia due to helminth infections in the
subsequent intervention period. These pre-medications
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comprised: (1) dihydroartemisinin-piperaquine (Sigma-
Tau, Rome, Italy; tablets of 40 mg of dihydroartemisinin
and 320 mg of piperaquine), for 3 days at a daily target
dose of 4 mg/kg body weight [24]; (2) albendazole
(Indoco Remedies, Mumbai, India), for 3 days at a daily
target dose of 200 mg or 400 mg for children aged
12–24 months and >24 to 36 months, respectively; (3)
praziquantel (Cosmos, Nairobi, Kenya; 600-mg tablets),
as a single dose at a target dose of 40 mg/kg body weight
[25]. Piperaquine is eliminated slowly (mean elimin-
ation half-life: 23 days in children in Burkina Faso)
[26], resulting in a protective efficacy against malaria
for at least 1 month [27, 28]. Medical staff observed
that the child swallowed the first dose of the pre-
medication drugs at the research clinic. Parents were
instructed to administer the remaining two doses of
dihydroartemisinin-piperaquine and albendazole at
home on the subsequent 2 days.
Eligibility
Children were eligible for enrolment in the study after
attaining the following eligibility criteria: aged 12–36
months; the child was expected to remain resident in
the study area for the duration of the intervention and
follow-up; no known or reported allergy to pre-
medication drugs; not severely malnourished (weight-
for-height z-score < –3 SD); absence of fever (axillary
temperature <37.5 °C); absence of reported or suspected
systemic disorders (e.g. HIV infection, tuberculosis,
sickle cell disease); haemoglobin concentration ≥70 g/L;
and at least one parent signed an informed consent form.
Of the 433 children screened between April and July 2014,
338 children were randomised for intervention. In our sam-
ple size calculations [29–31], we specified a non-inferiority
margin for haemoglobin concentration of 4.7 g/L, which
we expected to preserve 50% of the reported and an-
ticipated minimum effect of 12.5 mg ferrous fumarate
(9.3 g/L, [32]; Additional file 1).
Randomisation
Three days after the screening visit, children who met
the eligibility criteria were randomised at the research
clinic. We used a stratified block design to achieve group
balance in size and baseline haemoglobin concentration.
A person not involved in the fieldwork assigned the
three treatment groups to a sequence of random
permuted blocks of sizes 6 or 9 nested within two strata
defined by baseline haemoglobin concentration class
(<100 g/L and ≥100 g/L), using tables with random
numbers and random permuted blocks. Following this
scheme, two other persons not involved in the fieldwork
produced a set of labels with a child’s identification
number that included a letter for stratum (A or B) and a
consecutive allocation number as indicated by the
randomisation scheme. At the randomisation visit, the
trial coordinator assigned children successively to the
next available allocation number randomised for treat-
ment and according to appropriate stratum.
Composition of fortificants
We used three types of micronutrient powders that
contained vitamin A and zinc contents as per WHO
recommendations [1], 11 other micronutrients (Table 1)
at doses as recommended by the Home Fortification
Technical Advisory Group [33] and, in addition, either
3 mg iron as NaFeEDTA, or 12.5 mg iron as encapsu-
lated ferrous fumarate, or no iron (placebo). The micro-
nutrient powders were packed in 1-g plain white foil
single-serve sachets that were identical in appearance
and that did not result in apparent differences in taste,
texture or colour of uji (porridge made of maize flour).
We excluded folic acid because of concerns that it may
cause failure of antifolate drugs and because of the
absence of evidence that folate deficiency anaemia is a
public health problem among children in developing
countries [34].
Blinding
Researchers, outcome assessors and parents remained
blinded to the type of treatment allocated to each child
until the 30-day intervention period had been com-
pleted. At this point they were partially unblinded to
know if the child was in the placebo or iron group.
Table 1 Composition of home fortificants
Micronutrient Content
Vitamin A 300 μg RE
Vitamin D 5 μg
Vitamin E 5 mg
Vitamin C 30 mg
Thiamin (vitamin B1) 0.5 mg
Riboflavin (vitamin B2) 0.5 mg
Niacin (vitamin B3) 6 mg
Vitamin B6 (pyridoxine) 0.5 mg
Vitamin B12 (cobalamin) 0.9 μg
Iron
EITHER iron as encapsulated ferrous fumarate 12.5 mg
OR iron as NaFeEDTA 3 mg
OR no iron (placebo) 0 mg
Zinc 5 mg
Copper 0.56 mg
Selenium 17 μg
Iodine 90 μg
RE retinol equivalents
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Investigators were fully unblinded after the fieldwork
was complete and the statistical analysis plan written.
Adherence monitoring
Adherence to intervention was monitored using an
electronic monitoring and time-recording device (Medica-
tion Events Monitoring Systems, MEMS, 6 TrackCap
45 mm without LCD display; WestRock, Sion, Switzerland;
http://www.medamigo.com/) that is considered to be the
reference standard and superior to medication counts and
self-reported adherence methods [35, 36]. The battery-
operated device consists of a cap with a built-in micropro-
cessor that fits the bottle with the micronutrient sachets. It
records and internally stores dates and times of all open-
ings. Parents were taught how to use the bottle with the
electronic device without knowing that the device was
monitoring the openings of the bottle and instructed to
return the electronic device with any remaining sachets at
the end of 30 days of intervention.
Intervention period
On the first day of intervention, research assistants gave
parents a supply of 30 sachets in a plastic bottle with a
MEMS cap and instructed them to add the contents of a
single-serve sachet to the child’s semi-solid, ready-
prepared foods every day for a period of 30 days. The
main staple food consumed by pre-school children was
uji made from locally milled flour from either maize or
sorghum grains. The grains are not de-germed and sifted
and so have high contents of phytic acid and phenolic
compounds [37, 38]. At the research clinic, the assistants
showed parents how to mix the contents of the first
sachet with uji. This first dose was consumed at the
research facility, and trained research assistants closely
observed that each child consumed all the uji. Parents
were given a mosquito net and instructed to immediately
inform research assistants whenever a child fell sick. Re-
search assistants conducted weekly pre-announced home
visits to check if parents were adhering to instructions
given at randomisation. Sick children found in the homes
were referred to the research clinic. Children with fever
(≥37 °C) and who tested positive for Plasmodium infection
by microscopic examination of blood smears were treated
immediately with artemisinin-lumefantrine; during treat-
ment, these children were temporarily discontinued from
the intervention treatment until medication was com-
pleted and subsequent microscopic examination of blood
smears conducted after 7 days showed negative for
malaria parasites.
Parents who withdrew children from the intervention
were asked for reasons and permission to keep and analyse
data and samples already collected. After 30 days of inter-
vention, the phlebotomist collected venous blood (4 mL)
and processed samples as stated above (Data collection time
lines and field procedures). Medical staff examined every
child, and fieldworkers collected anthropometric data, plas-
tic bottles with the MEMS cap and empty sachets and ad-
ministered a questionnaire to parents to collect additional
information on possible factors affecting adherence. Once
all data and samples were collected, the trial coordinator
opened the sealed brown envelope to find out the child’s
intervention group (either iron or placebo).
Post-intervention period
For ethical reasons, children in the placebo group were
given a 3-day course of dihydroartemisinin-piperaquine
and a subsequent 30-day course of home fortification
with 12.5 mg iron as encapsulated ferrous fumarate.
Children in the iron group were retained without fortifi-
cation powders to monitor the population decline in
haemoglobin concentration over time in a 100-day
follow-up period. Parents were requested to take each
child home and bring them back to the research clinic on
a date generated by a pre-programmed Microsoft Excel
software that randomly selected a date of their return visit
within a 100-day period. On the return visit, a capillary
blood sample was collected by finger puncture to measure
haemoglobin concentrations in duplicate from a single
drop and to store DNA on collection cards for subsequent
assessment by PCR assay of Plasmodium parasites. Imme-
diately, these children were withdrawn from further study
and received appropriate medication if sick, a therapeutic
course of dihydroartemisinin-piperaquine and a supply of
sachets for daily home fortification with 12.5 mg iron as
encapsulated ferrous fumarate for another 30 days.
Laboratory analysis
We determined haemoglobin concentration (HemoCue
301, Ängelholm, Sweden) and zinc protoporphyrin
(ZPP)-haem molar ratio (AVIV, model 206D, Lakewood
NJ, USA) in whole blood and in erythrocytes as a marker
of iron-deficient erythropoiesis, each in triplicate. We
assayed Plasmodium antigenaemia by histidine-rich pro-
tein 2 (HRP2) and lactate dehydrogenase (LDH) tests
and transferred aliquots of whole blood (125 μL) on
DNA collection cards (FTA Mini Card, catalogue
WB120055, GE Healthcare, Little Chalfont, UK) for stor-
age at ambient temperature and subsequent detection by
PCR of Plasmodium infection; we also prepared thick
and thin blood smears to allow for detection and count-
ing of Plasmodium parasites. Iron markers (plasma con-
centrations of ferritin, soluble transferrin receptor and
transferrin), inflammation markers (plasma concentra-
tions of C-reactive protein (CRP) and α1-acid glycopro-
tein), albumin and vitamin B12 were measured at
Meander Medical Centre, Amersfoort, The Netherlands,
on an Abbott Architect C16000 and i2000 SR analyser
as per manufacturer’s instructions.
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Statistical analysis
Details of the statistical analysis are presented in a sup-
plementary paper (Additional file 1). Data were double
entered, checked for completeness and verified for pos-
sible entry errors using Microsoft Excel. Anthropometric
indices and electronic adherence data were analysed
using WHO Anthro software v.3.2.2 (World Health Or-
ganisation, Geneva, Switzerland) and PowerView v.3.5.2
(AARDEX Group Ltd, Sion, Switzerland), respectively.
The final statistical analysis was conducted using
SPSS 21 (IBM, Armonk, NY, USA) and CIA 2.2.0
(https://eprints.soton.ac.uk/393017/). To assess EDTA in-
take at home fortification levels of 3 mg iron as
NaFeEDTA, we calculated the intake of iron per kilogram
of body weight for all children in the trial, both at baseline
and at 30 days after intervention. The corresponding in-
take of NaFeEDTA (NaFeC10H12N2O8) was calculated as
intake iron × (molecular weightEDTA/molecular weightIron)
= intake iron × (288.21/55.88). From these results, we
assessed the prevalence of EDTA intake exceeding the
upper level of the acceptable daily intake (ADI) (i.e. the
amount of a food additive, expressed on a body weight
basis, that can be ingested daily over a lifetime without ap-
preciable health risk [39]) to be 1.9 mg/kg body weight
[40].
The definitions we used were anaemia: haemoglobin
concentration <110 g/L [41]; iron deficiency: plasma
ferritin concentration <12 μg/L [42]; Plasmodium infec-
tion: presence of parasites and gametocytes of any
Plasmodium species [43]; inflammation: plasma CRP
concentration >5 mg/L [44] or plasma α1-acid glycopro-
tein concentration >1.0 g/L [45], respectively. Group ad-
herence was defined as the proportion of children who
consumed ≥24 home fortification doses, corresponding
to ≥80% of the 30 scheduled doses [46], with exclusion
of children who were lost to follow-up because they
moved out of the study area.
Variation of outcomes with a log-normal distribution
was expressed as geometric standard deviation (GSD),
i.e. a multiplicative factor such that division or multipli-
cation of the geometric mean by this ratio indicates a
variation that is equivalent to subtraction or addition of
one standard deviation on a log-transformed scale [47].
Plasma ferritin concentration can be elevated by
inflammation independently of iron status. Thus, when
estimating the prevalence of iron deficiency, we
accounted for inflammation by two methods. First, we
restricted the analysis to children without inflammation.
This method has the disadvantages that it leads to a
reduced statistical precision (because of the reduced
sample size) and it may produce biased results (if the
true prevalence of iron deficiency differs between those
with and without inflammation). Second, we used linear
regression to adjust plasma ferritin concentrations for
plasma concentrations of CRP and α1-acid glycoprotein
concentration. We used the following formula for
adjustment: loge(ferritinadjusted) = loge(ferritinunadjusted) –
β1[loge(CRPobserved) – loge(CRPreference)] – β2 [loge(AG-
Pobserved) – loge(AGPreference)]; the results were then
exponentiated to express ferritin concentrations in their
natural units. The formula given here is similar to what
was recently proposed [48]; however, we used log-
transformed values because of the linear relationship
that has been observed between log-ferritin and log-
CRP, as well as between log-ferritin and log-α1-acid
glycoprotein (Suchdev, personal communication, 2016;
and also the present study (not shown)). We used
15 mg/L and 2.59 g/L as reference values for CRP and
α1-acid glycoprotein, respectively, because these values
were reported as the upper limits of the 95% reference
range in healthy French children aged 3–5 years [49].
We implicitly assumed that higher upper values for
reference ranges, as can be observed in their peers in
developing countries, are due to infections and other
inflammation-inducing disorders.
The objective of non-inferiority was determined by
comparing end points obtained by both intention-to-
treat and per protocol analyses. We visually inspected
histograms to assess whether outcome variables were
normally distributed within intervention groups.
Outcome variables with a log-normal distribution were
log-transformed; exponentiation of group differences in
log-transformed outcomes resulted in associations being
expressed as relative differences. Outcomes that were
not normally distributed, even after log-transformation,
were compared using non-parametric tests. We esti-
mated effects; p values, where reported, are two-sided.
For the primary analysis, we estimated the difference
in haemoglobin concentrations at the end of the 30-day
fortification period between groups of children allocated
to different iron formulations. Analysis was done using
analysis of variance (ANOVA) and multiple linear re-
gression analysis. As pre-planned, we accepted non-
inferiority only when all of the following conditions were
met: (1) home fortification with 3 mg iron as NaFeEDTA
was superior to placebo (proof of efficacy); (2) home
fortification with 12.5 mg iron as encapsulated ferrous
fumarate was superior to placebo (proof of assay sensi-
tivity); and (3) the lower limit of the 95% confidence
interval (CI) around the difference in haemoglobin
concentration between the groups who received home
fortification with the two different iron formulations ex-
cluded the non-inferiority margin of 4.7 g/L, in both
intention-to-treat and per protocol analyses (proof of
efficacy).
For the secondary analysis, we used stratified analysis
and multiple linear regression models to control for
group imbalances of baseline factors that were strongly
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or moderately associated with primary outcome and
were likely to influence the effect estimates. These base-
line factors were plasma ferritin concentration, plasma
soluble transferrin receptor concentration and age.
Subgroup analysis
Because iron absorption is known to depend on iron
status, we considered iron markers at baseline (anaemia,
iron status) as potential modifiers for intervention ef-
fects on haemoglobin concentration and plasma ferritin
concentration at the end of the 30-day intervention
period. Stratified analysis was used to measure effect
sizes within subgroups; evidence for group differences in
intervention effects was formally investigated in multiple
linear regression models that included intervention and
each baseline factor as main terms, as well as their prod-
uct term. We conducted all three possible paired group
comparisons (12.5 mg iron as ferrous fumarate versus
3 mg iron as NaFeEDTA; 12.5 mg iron as ferrous fumarate
versus placebo; 3 mg iron as NaFeEDTA versus placebo).
In these analyses, we adjusted for plasma concentrations
of ferritin and transferrin receptor at baseline (both as
continuous variables); in the analysis of plasma ferritin
concentration at 30 days after start of intervention, these
baseline variables were log-transformed because this gave
a better model fit than the untransformed variables.
Meta-analysis
We conducted a meta-analysis of randomised controlled
trials in pre-school children to assess the effect of home
fortification with iron-containing powders on anaemia
and haemoglobin concentration at end of intervention.
The methods are described in Additional file 2.
Results
Flow of participants
Of 433 children who were invited for screening, 366 chil-
dren met the criteria for pre-medication administration
and 338 children were randomised. Of these, 315 (93.5%)
completed 30 days of the intervention period and were in-
cluded in the per protocol analysis (Fig. 1). Reasons for
loss to follow-up were refusal by parents (n = 8), moving
out of the study area (n = 6) and unknown (n = 9).
A total of 80 children became sick during the 30-day
intervention period. We found no evidence that the pro-
portion of sick children varied between intervention
groups (p = 0.13). The most common infections were
uncomplicated malaria with upper respiratory tract in-
fections (24), severe malaria (14), upper respiratory tract
infections (11) and uncomplicated malaria (8). Overall,
200 (60.6%) of the children consumed more than 80%
(>24) of 30 scheduled sachets, and there was no evi-
dence that this percentage differed between intervention
groups (p = 0.99).
Baseline characteristics
The intervention groups were similar with respect to
baseline characteristics (Table 2). Overall, the mean age
was 23.6 months; 62.1% of children had anaemia.
Inflammation as indicated by elevated concentrations of
CRP or α1-acid glycoprotein occurred in 66.9% (226/
338) of children. The prevalence of iron deficiency was
17.1% (57/333) or 42.5% (57/134), depending on whether
or not children with inflammation were excluded from
analysis. With ferritin concentrations adjusted for in-
flammation by linear regression, the prevalence of iron
deficiency was 53.2% (177/333). Of 366 blood samples
assessed for the presence of P. falciparum by microscope
or rapid dipstick tests (HRP2 or P. falciparum-specific
pLDH), 40.7% and 36.4% of children were positive, re-
spectively, with a median (25th, 75th percentiles) density
of asexual parasites of 1410 (207, 682) μ/L. The preva-
lence of being stunted, wasted and underweight was
30.1%, 3.3% and 13.9%, respectively.
EDTA intake
Home fortification with 3 mg iron as NaFeEDTA
resulted in a mean intake (SD) of 1.48 (0.24) EDTA/kg
body weight and 1.44 (0.23) EDTA/kg body weight at
baseline and at 30 days after the start of intervention,
respectively (Fig. 2). Correspondingly, assuming that this
intake follows a normal distribution, 4.0% and 2.0% of
children would exceed the ADI for EDTA of 1.9 mg/kg
body weight.
Intervention effects
In the per protocol analysis, there was no evidence that
home fortification for 30 days, whether using a daily
dose of 3 mg iron as NaFeEDTA or 12.5 mg iron as
ferrous fumarate, was efficacious in improving haemo-
globin concentration, plasma ferritin concentration,
plasma transferrin receptor concentration or erythrocyte
ZPP-haem ratio (Table 3). Adjustment for baseline
factors that were prognostic for haemoglobin concentra-
tion did not substantially change intervention effects
(haemoglobin concentration difference of 1.3 g/L (–1.8 g/L
to 4.3 g/L). Similarly, the intention-to-treat analysis
(Additional file 3: Table S2) led to virtually identical results
as obtained by per protocol analysis, and restriction of the
analysis to children without inflammation led to similar ef-
fect estimates on haemoglobin concentration (0.9 g/L, –4.1
to 5.9 g/L and 2.3 g/L, –3.1 to 7.8 g/L for 3 mg iron as
NaFeEDTA and 12.5 mg iron as ferrous fumarate, respect-
ively). Given these results, we conducted no further
analysis to demonstrate non-inferiority of 3 mg iron as
NaFeEDTA.
Compared to placebo, home fortification with 3 mg iron
as NaFeEDTA seemed to reduce the prevalence of iron
deficiency by 20.2% (Table 4); one-quarter of children who
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received this iron formulation nonetheless remained
anaemic after 30 days. Home fortification with 12.5 mg
iron as ferrous fumarate seemed to reduce the prevalence
of iron deficiency by 14.1% (95% CI: –3.5 to 30.7%), but
the statistical evidence for such a reduction, as judged by
the 95% CI, was weak. There was no evidence that either
of the iron interventions affected the prevalence of
anaemia, which affected one-half of children at the end of
the 30-day intervention period, or the prevalence of
Plasmodium infection, which remained at 16.4–19.1%,
depending on the method of assessment.
Subgroup analysis
There was no evidence that the effect of home fortifica-
tion with iron, whether administered at a daily dose of
3 mg iron as NaFeEDTA or 12.5 mg iron as encapsulated
ferrous fumarate, on haemoglobin concentration or
plasma ferritin concentration was modified by iron status
or anaemia status at baseline (see Figs. 3 and 4). The effect
of home fortification with 12.5 mg iron as ferrous fumar-
ate on increased plasma ferritin concentration seemed
larger in children without inflammation than in their
peers with inflammation at baseline (89% versus 3%), but
the statistical evidence of such an effect modification was
weak (p interaction: 0.17; Fig. 4).
Meta-analysis
The effect on haemoglobin concentration was highly
heterogeneous (I2: 8.1%; p value for test of heterogen-
eity: <0.0001; Additional file 2: Figure S4). The pooled
effect on haemoglobin concentration was 3.9 g/L
(95% CI: 2.2–5.50 g/L), indicating that in a random
sample of a hypothetically infinite number of trials,
each estimating a different true underlying effect, one
may on average expect an increase in haemoglobin
concentration by 3.9 g/L, with the 95% CI excluding
an effect beyond 5.5 g/L.
Discussion
We found no evidence that daily home fortification for
30 days with a daily dose of either 3 mg iron as
NaFeEDTA or 12.5 mg iron as encapsulated ferrous
fumarate was efficacious in improving haemoglobin
concentration or iron markers (plasma ferritin concen-
tration, plasma soluble transferrin receptor concentra-
tion or erythrocyte ZPP-haem ratio). Compared to
placebo, however, home fortification with 3 mg iron as
NaFeEDTA reduced the prevalence of iron deficiency by
20.2% (44.6% versus 24.5%; Table 4). Meta-analysis of
trial results indicates a small, heterogeneous effect of
home fortification with iron-containing powders on
haemoglobin concentration.
Dichotomising a continuous outcome variable has the
disadvantages that individuals close to but on opposite
sides of the cut-off value are characterised as being very
different rather than very similar [50], and that the
prevalence difference depends on the cut-off value used
for dichotomisation of the outcome [51]. Thus, in our
study, a small group difference in the distribution of
plasma ferritin concentration may misleadingly result in
Fig. 1 Participant flow through the trial. *Sample sizes below number indicated are due to missing values, which varied by outcome. In the
intention-to-treat analysis, missing values were replaced by multiple imputation
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Table 2 Baseline characteristics, by intervention group
Characteristic Placebo Iron, 3 mg as
NaFeEDTA
Iron, 12.5 mg as
ferrous fumarate
Number (n) 112 112 114
General characteristics
Sex, male 69 (61.6%) 61 (54.5%) 56 (49.1%)
Age, months 22.8 (6.8) 23.2 (6.2) 24.9 (6.4)
Age class
12–23 months 61 (54.5%) 57 (50.9%) 44 (38.6%)
24–36 months 51 (45.5%) 55 (49.1%) 70 (61.4%)
Nutritional markers
Haemoglobin concentration, g/L 104.4 (13.2) 105.9 (13.3) 104.7 (13.3)
Anaemia
Moderate (haemoglobin concentration 70–99.99 g/L) 33 (29.5%) 34 (30.4%) 36 (31.6%)
Mild (haemoglobin concentration 100–109.99 g/L) 39 (34.8%) 31 (27.7%) 37 (32.5%)
No anaemia (haemoglobin concentration ≥110 g/L) 40 (35.7%) 47 (42.0%) 41 (36.0%)
ZPP:haem ratio, μmol:mola
In whole blood 170 (119; 305) 172 (102; 260) 196 (137; 283)
In erythrocytes 130 (84; 301) 141 (76; 223) 160 (101; 246)
Plasma ferritin concentration, μg/La,b 37.7 (17.3; 74.0) 31.4 (16.0; 56.6) 36.9 (17.6; 68.8)
Iron statusb
Deficient (plasma ferritin concentration <12 μg/L) 17 (15.2%) 20 (18.3%) 20 (17.9%)
Replete (plasma ferritin concentration ≥12 μg/L in
the absence of inflammation)
26 (23.2%) 32 (29.4%) 19 (17.0%)
Uncertain (plasma ferritin concentration ≥12 μg/L in
the presence of inflammation)
69 (61.6%) 57 (52.3%) 73 (65.2%)
Iron deficiency, based on adjusted ferritin concentrationsb,c 52.7% (59/112) 57.8% (63/109) 49.1% (55/112)
Plasma soluble transferrin receptor concentration, mg/La 2.41 (1.75; 3.46) 2.39 (1.82; 3.16) 2.60 (1.93; 3.41)
Plasma albumin concentration, g/L 34.6 (3.9) 35.0 (3.5) 34.7 (4.1)
Vitamin B12 concentration, pmol/L 391 (291; 557) 409 (311; 569) 401 (315; 554)
Infection and inflammation markers
Plasma C-reactive protein concentration, mg/La 2.5 (0.7; 7.6) 2.5 (0.6; 7.8) 4.5 (1.3; 11.0)
Plasma α1-acid glycoprotein concentration, g/La 1.20 (0.90; 1.57) 1.08 (0.81; 1.47) 1.17 (0.97; 1.63)
Inflammation
Plasma C-reactive protein concentration >5 mg/L 40 (35.7%) 35 (31.3%) 53 (46.5%)
Plasma α1-acid glycoprotein concentration >1 g/L 71 (63.4%) 63 (56.3%) 81 (71.1%)
Plasma C-reactive protein concentration >5 mg/L or plasma
α1-acid glycoprotein concentration >1 g/L
77 (68.8%) 65 (58%) 84 (73.7%)
Plasmodium antigenaemia, by rapid dipstick testsd
P. falciparum (either HRP2 or P. falciparum-specific pLDH) 39 (35.1%) 40 (36.0%) 43 (38.1%)
Plasmodium species other than P. falciparum (pLDH specific for
P. malariae, P. ovale or P. vivax)e
1 (0.9%) 2 (1.8%) 0
Any Plasmodium species 39 (35.1%) 41 (36.9%) 43 (38.1%)
Blood smear tests, by microscopy
Asexual or sexual forms of P. falciparum 47 (41.9%) 49 (43.8%) 55 (48.2%)
Asexual forms of both P. falciparum and human Plasmodium
spp. other than P. falciparum (i.e. P. malariae, P. ovale or P. vivax)
2 (1.8) 1 (0.8) 2 (1.8)
Asexual parasite density for P. falciparum, μ/La 757 (172; 3972) 3340 (297; 20,023) 1048 (207; 6820)
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a relatively large difference in prevalence of iron
deficiency. For this reason, group differences in the
prevalence of iron deficiency should be interpreted with
caution, and more weight should be given to group
differences in plasma ferritin concentrations.
Adherence to intervention was suboptimal, with a sub-
stantial proportion of children (~40%) having consumed
<80% of the scheduled sachets. We found no evidence of
bias in effect estimates due to differences in baseline fac-
tors that were prognostic for haemoglobin concentra-
tion. Our failure to show efficacy for either compound
was found in both the per protocol and intention-to-
treat analyses, was consistent across subgroups that were
defined by anaemia and iron status and precluded
further assessment of the non-inferiority of 3 mg iron as
NaFeEDTA compared to 12.5 mg iron as encapsulated
ferrous fumarate.
Despite a course of chemoprevention with dihydroar-
temisinin-piperaquine, a substantial proportion of
children carried Plasmodium parasites at the end of the
30-day intervention period. When assessed by rapid
dipstick tests, this proportion may be overestimated
because the P. falciparum HRP2 protein can persist in
circulation for several weeks after parasite clearance
[52, 53]. We nonetheless found a similar prevalence
estimate by microscopy, suggesting recrudescence of
infections or the occurrence of new infections. In 2015,
WHO revised the recommended target oral doses for mal-
aria treatment with dihydroartemisinin and piperaquine in
children, in recognition that the previously recommended
dosage schedule (which was used in the present study)
may be inadequate and may predispose children to an
increased risk of treatment failure [54]. In addition, poor
adherence to the second and third doses of dihydroarte-
misinin-piperaquine administered by parents at home
may also have contributed to the recurrence of malaria.
Future studies should consider direct observation of
adherence to all doses during the entire course.
We selected a relatively short 30-day intervention with
iron in the expectation that pre-medication with
dihydroartemisinin-piperaquine would prevent malaria
during this period, with a long-term view that the pro-
tection afforded by repeated chemoprevention with this
combination drug would allow time windows for safe
administration of short courses of iron intervention. The
duration of protection of a single course of dihydroarte-
misinin-piperaquine is likely to vary between individuals
and populations, depending, among other things, on
variance in absorption and disposition of piperaquine
and levels of acquired immunity (and thus on age and
frequency and duration of exposure to Plasmodium in-
fection). In a recent study among pre-school children in
Burkina Faso, two cycles of chemoprevention with
dihydroartemisinin-piperaquine, administered at the
same target dose as in our study, resulted in a protection
against malaria that persisted at a high level for 3 to
4 weeks and decreased rapidly thereafter, highlighting
the importance of strict timing to ensure that children
receive treatment at monthly intervals [55].
Our data show that the fortification dose of 3 mg iron
as NaFeEDTA cannot be increased without a substantial
proportion of children in this age range exceeding the
ADI for EDTA. It has been argued, however, that this
ADI may have been set too low [56], and a recent trial
Table 2 Baseline characteristics, by intervention group (Continued)
Low (<1000 μ/L) 17 (15.2%) 9 (8.0%) 19 (16.7%)
Medium (1000–9999 μ/L) 12 (10.7%) 8 (7.1%) 15 (13.2%)
High (≥10,000 μ/L) 3 (2.7%) 7 (6.3%) 5 (4.4%)
Gametocyte density, μ/La 326 (49; 732) 82 (37; 120) 1126 (57; 2679)
Anthropometric markers
Body height, cm 80.9 (5.9) 82.1 (5.7) 82.4 (5.1)
Body weight, kg 10.6 (1.8) 10.8 (2.0) 10.9 (1.7)
Height-for-age z-score, SD –1.42 (1.47) –1.15 (1.43) –1.43 (1.31)
Weight-for-height z-score, SD –0.10 (1.05) –0.16 (1.07) –0.14 (0.93)
Weight-for-age z-score, SD –0.81 (1.18) –0.71 (1.22) –0.86 (1.09)
Stunted (height-for-age z-score < –2 SD) 34 (30.4%) 31 (27.7%) 37 (32.5%)
Wasted (weight-for-height z-score < –2 SD) 3 (2.7%) 5 (4.5%) 2 (1.8%)
Underweight (weight-for-age z-score < –2 SD) 19 (17.0%) 12 (10.7%) 15 (13.2%)
Values indicate n (%), mean (SD) or amedian (25th and 75th percentiles). HRP2 histidine-rich protein-2, pLDH P. falciparum-specific lactate dehydrogenase
bDue to missing values for ferritin concentrations in 5 children, n was 112, 109 and 112 for groups that received placebo, NaFeEDTA and ferrous fumarate,
respectively; cbased on ferritin concentrations adjusted for inflammation by linear regression (see text)
dDue to missing values in 3 children, n was 111, 111 and 113 for groups that received placebo, NaFeEDTA and ferrous fumarate, respectively
eOne child in placebo group and 1 child in NaFeEDTA group with antigenaemia due to P. malariae or P. ovale or P. vivax also had antigenaemia to P. falciparum
(mixed infection)
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in Moroccan children has shown that daily oral intake of
EDTA can reduce blood lead concentrations [57], which
is important in view of the enormous public health
burden due to lead exposure in developing countries.
The question may be raised whether our intervention
period of 30 days was too short to show an effect on
haemoglobin concentrations. In an earlier placebo-
controlled randomised trial among Kenyan children aged
2–36 months, it was shown with a smaller sample size
(79 iron; 76 placebo) than the present study that weekly
supplementation with 6 mg elemental iron as ferrous
fumarate per kilogram body weight improved haemoglo-
bin concentration at 4 weeks after the start of interven-
tion [58]. Several other trials with longer intervention
periods of home fortification also failed to demonstrate
haematological response to home fortification with iron.
For instance, a randomised trial in 6-month old Kenyan
infants showed no effect of daily home fortification with
2.5 mg iron as EDTA on haemoglobin concentration
after 6 and 12 months of intervention [59]. Similarly, a
trial conducted among Ghanaian children aged 8–20
months failed to show an effect on haemoglobin concen-
tration after 6 months of daily home fortification with
40 mg elemental iron as microencapsulated ferrous
fumarate [60]. These findings suggest that there are
other underlying factors that may cause a lack of effect
of iron interventions on haemoglobin concentration.
Inflammation was highly prevalent and is known to re-
duce iron absorption. In our subgroup analysis, however,
there was no evidence that inflammation at baseline
influenced the magnitude of the effect of iron interven-
tions on haemoglobin concentration, and only weak
evidence (p = 0.17) that it decreased the effect of home
fortification with 12.5 mg iron as ferrous fumarate on
plasma ferritin concentration. However, the cut-off def-
inition for inflammation levels has not been validated in
children, so there is a possibility that iron absorption
was impaired at levels of inflammatory markers within
the normal range (plasma CRP concentration <5 mg/L
or plasma α1-acid glycoprotein concentration <1.0 g/L).
Chronic infections caused by either viruses or low bac-
terial and parasitic loads can increase the inflammatory
cytokine-mediated production of hepcidin, thus blocking
iron absorption, in the absence of evident inflammation
(Rita Wegmuller, personal communication, 25 May 2016).
The notion that infection-induced inflammation can
reduce iron absorption is supported by the findings of a
study conducted among Gambian children aged 18–36
months, which showed elevated serum CRP concentra-
tions and impaired absorption of orally supplemented iron
in children with post-malarial anaemia compared with
those with non-malarial anaemia, but serum CRP concen-
trations had reversed and iron absorption was recovered
at 2 weeks after antimalarial treatment [61]. Another study
among Kenyan infants showed that both low doses
(2.5 mg iron as NaFeEDTA) and a high dose (12.5 mg iron
as ferrous fumarate) increased the pathogenic profile of
gut bacteria and gut inflammation [7].
Other factors that may have contributed to our failure
to show efficacy are high contents of iron-inhibiting
factors such as phytates and polyphenolic compounds in
the food vehicles used for home fortification and
suboptimal adherence to the daily home fortification
with iron-containing powders.
The use of placebo in non-inferiority trials is contro-
versial. Some argue that it is unethical to use placebos in
the context of established interventions that have been
shown to be efficacious [62, 63]. The Declaration of
Helsinki (2013) asserts that ‘the benefits, risks, burdens
Fig. 2 EDTA intake at daily home fortification levels of 3 mg iron as
NaFeEDTA, at baseline (a) and at 30 days after start of intervention
(b). The acceptable daily intake (ADI) for EDTA is <1.9 mg/kg
body weight
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Table 3 Effect of daily home fortification with 3 mg iron as NaFeEDTA and 12.5 mg iron as encapsulated ferrous fumarate on
continuous outcomes at 30 days after start of intervention, per protocol analysis
Outcome/intervention group No. (n) Estimatea Effect (95% CI) relative to placebob Effect (95% CI) relative to standardb
Haemoglobin concentration
Placebo 105 106.9 g/L (13.3 g/L) Reference Not applicable
Iron, 3 mg as NaFeEDTA 103 110.0 g/L (12.5 g/L) 3.0 g/L (–0.2 g/L to 6.2 g/L)c 1.3 g/L (–1.8 g/L to 4.3 g/L)c
Iron, 12.5 mg as ferrous fumarate 107 108.6 g/L (12.0 g/L) 1.6 g/L (–1.6 g/L to 4.8 g/L)c Reference
Plasma ferritin concentration
Placebo 104 29.7 μg/L [3.47] Reference Not applicable
Iron, 3 mg as NaFeEDTA 102 33.7 μg/L [2.53] 16.2% (–14.3% to 57.7%)d 2.5% (–22.4% to 35.4%)d
Iron, 12.5 mg as ferrous fumarate 105 32.6 μg/L [3.00] 12.3% (–17.1% to 52.0%)d Reference
Plasma soluble transferrin receptor concentration
Placebo 105 2.24 mg/L [1.61] Reference Not applicable
Iron, 3 mg as NaFeEDTA 103 2.15 mg/L [1.47] –4.3% (–13.5% to 5.9%)d 3.6% (–5.5% to 13.6%)d
Iron, 12.5 mg as ferrous fumarate 106 2.07 mg/L [1.38] –7.3% (–16.2% to 2.6%)d Reference
Erythrocyte ZPP-haem ratio
Placebo 104 136 μmol/mol [2.17] Reference Not applicable
Iron, 3 mg as NaFeEDTA 103 127 μmol/mol [1.97] –6.5% (–23.5% to 14.2%)d -5.3% (-21.7% to 14.5%) d
Iron, 12.5 mg as ferrous fumarate 106 134 μmol/mol [2.00] –0.7% (–18.6% to 21.0%)d Reference
aMean (SD) or geometric mean [geometric standard deviation]
bEffects were adjusted for study design (blocks nested within strata of haemoglobin concentration <100 g/L and ≥100 g/L)
cEffects were calculated as absolute difference in means
dExponentiation of group differences with log-transformed outcomes resulted in associations being expressed as relative differences
Table 4 Effect of daily home fortification with 3 mg iron as NaFeEDTA and 12.5 mg iron as encapsulated ferrous fumarate on
categorical outcomes at 30 days after start of intervention, per protocol analysis
Outcome/intervention group Prevalence (n/n) Effect (95% CI) relative to placebo
Anaemia
Placebo 53.3% (56/105) Reference
Iron, 3 mg as NaFeEDTA 43.7% (45/103) –9.6% (–22.7% to 3.9%)
Iron, 12.5 mg as ferrous fumarate 51.4% (55/107) –1.9% (–15.1% to 11.3%)
Iron deficiencya
Placebo 44.6% (25/56) Reference
Iron, 3 mg as NaFeEDTA 24.5% (12/49) –20.2% (–36.4% to –18.5%)
Iron, 12.5 mg as ferrous fumarate 30.5% (18/59) –14.1% (–30.7% to 3.5%)
Plasmodium infection, by dipstick testb
Placebo 16.2% (17/105) Reference
Iron, 3 mg as NaFeEDTA 18.4% (19/103) 2.3% (–8.1% to 12.6%)
Iron, 12.5 mg as ferrous fumarate 22.6% (24/106) 6.4% (–4.3% to 17.0%)
P. falciparum infection, by microscopy
Placebo 18.5% (19/103) Reference
Iron, 3 mg as NaFeEDTA 15.5% (15/97) –3.0% (–13.4% to 7.6%)
Iron, 12.5 mg as ferrous fumarate 15.2% (15/99) –3.3% (–13.6% to 7.2%)
aAnalysis restricted to children without inflammation (see text)
bPresence of HRP, pLDH specific to P. falciparum or pLDH due to human Plasmodium species other than P. falciparum
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and effectiveness of a new intervention must be tested
against those of the best proven intervention(s)’ [64]. In
our case, there was an established WHO recommenda-
tion for daily home fortification with 12.5 mg iron as fer-
rous salt, based on a meta-analysis of six randomised
controlled trials [3] that showed an overall reduction of
the prevalence of anaemia.
We included a third arm with placebo, however,
because we were concerned that established efficacious
interventions do not consistently demonstrate superior-
ity in placebo-controlled studies. Notably, one-third of
meta-analyses that demonstrate a protective effect from
interventions are not supported by subsequent large
randomised controlled trials [65, 66]. In addition, in the
meta-analysis that formed the basis for the WHO
recommendation for daily home fortification, three of
six trials included could not exclude the absence of an
effect on haemoglobin concentration. A trial among
Ghanaian children, published after the meta-analysis but
before we started our study, with a larger sample size
than all previous studies combined, also failed to showed
an effect of daily home fortification with 12.5 mg iron as
ferrous fumarate on either change in haemoglobin
concentration or the prevalence of anaemia, despite 45%
of children being iron deficient at baseline and good ad-
herence to intervention [61]. Our use of a three-armed
non-inferiority trial that includes a placebo arm is con-
sistent with international recommendations [67] and is
validated by our results: in the absence of a placebo
group, we would erroneously have concluded that 3 mg
iron as NaFeEDTA was non-inferior to 12.5 mg iron as
encapsulated ferrous fumarate.
In our meta-analysis, we found a high level of hetero-
geneity in effects across trials. How should we interpret
this finding? In the absence of evidence for an effect in
single trials, meta-analysis is often understood to be the
continuation of the pursuit of statistical significance by
other means. A high level of heterogeneity indicates,
however, that there is no single true effect in a single,
common population that underlies the trials included in
the meta-analysis. Heterogeneity may reflect methodo-
logical differences between trials (dosage, formulation
and duration of intervention, adherence, study quality,
etc.), but it may also indicate that there are different
types of populations, each with different true underlying
effects. Thus, the pooled random effect may not reflect
the actual effect in any particular population being studied,
and has little value other than perhaps providing some
Fig. 3 Effect of interventions on haemoglobin concentration (g/L) at 30 days after start of intervention, by subgroups of iron status and haemoglobin
concentration class at baseline. Inflammation was defined to be absent when plasma C-reactive protein (CRP) concentration was ≤5 mg/L and plasma
α1-acid glycoprotein concentration was ≤1.0 g/L, and present when either plasma CRP concentration was >5 mg/L or plasma α1-acid glycoprotein
concentration was >1.0 g/L. Group means were obtained by one-way ANOVA. Intervention effects were adjusted for stratified block design as well as
plasma concentrations of ferritin and soluble transferrin receptor at baseline (both continuous variables). The p values indicate the two-sided probability
that group effects are as different as observed or more extreme when assuming that they are identical
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evidence to inform policy decisions. Our meta-analysis
(Additional file 2: Figure S4) suggests a small gain in
haemoglobin concentration in most trials, indicating that
home fortification with iron-containing micronutrient
powders provides some benefit across different settings.
This gain may be insufficient to recommend home fortifi-
cation in all settings, as illustrated by the main results of
our trial. Our finding of heterogeneity between trial results
should stimulate subgroup analysis or meta-regression to
identify population-specific factors that determine efficacy
(e.g. differences in prevalence of iron deficiency and
inflammation, food content of compounds that inhibit iron
absorption). Such approaches may become possible as
evidence is accrued from a variety of studies in different
settings.
Conclusions
In this population, home fortification with either 3 mg
iron as NaFeEDTA or 12.5 mg iron as encapsulated
ferrous fumarate was insufficiently efficacious to assess
non-inferiority of 3 mg iron as NaFeEDTA compared to
12.5 mg iron as encapsulated ferrous fumarate. Our
finding of heterogeneity between trial results should
stimulate subgroup analysis or meta-regression to iden-
tify population-specific factors that determine efficacy.
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